Journal ArticleDOI
Effectiveness of Low-Dose Crystalline Nicotinic Acid in Men With Low High-Density Lipoprotein Cholesterol Levels
Reads0
Chats0
TLDR
A low dose (1.5 g/d) of crystalline nicotinic acid causes an average 20% increase in HDL-C levels and significantly lowers triglyceride levels in both normolipidemic and hyperlipidemic patients with low HDL- C levels.Abstract:
Background: Hypoalphalipoproteinemia (low serum concentration of high-density lipoprotein cholesterol [HDL-C]) is a common pattern of dyslipidemia associated with coronary heart disease. High doses of nicotinic acid effectively raise HDL-C levels in this condition, but they are commonly accompanied by side effects. The efficacy of low doses of nicotinic acid that may produce fewer side effects has not been adequately studied. Objective: To determine the effects of low-dose nicotinic acid on HDL-C levels in patients with hypoalphalipoproteinemia. Methods: Forty-four men with low HDL-C levels ( Results: Of the 44 patients who entered the study, 37 completed the low-dose phase (1.5 g/d); the remaining patients were withdrawn because of side effects to nicotinic acid. Four other patients who completed the low-dose phase were excluded from the higher dose phase because of side effects that developed when they were receiving the low dose. Ten other patients withdrew during the high-dose phase because of side effects. In both groups, responses to nicotinic acid therapy tended to be dose-dependent. For both groups, the higher dose generally produced a greater reduction in apolipoprotein B—containing lipoproteins and a greater rise in HDL-C levels. However, for both groups, the low dose of nicotinic acid gave an average 20% increase in HDL-C levels. Conclusions: A low dose (1.5 g/d) of crystalline nicotinic acid causes an average 20% increase in HDL-C levels and significantly lowers triglyceride levels in both normolipidemic and hyperlipidemic patients with low HDL-C levels. Although the changes induced by this dose are less than those that can be achieved by a higher dose, the lower dose is better tolerated. Nicotinic acid may be useful in combined drug therapy for secondary prevention of coronary heart disease, and if higher doses cannot be tolerated, use of a lower dose should still be useful for producing a moderate rise in HDL-C levels in patients with hypoalphalipoproteinemia. (Arch Intern Med. 1996;156:1081-1088)read more
Citations
More filters
Journal ArticleDOI
Primary Prevention of Coronary Heart Disease: Guidance From Framingham: A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction
Scott M. Grundy,Gary J. Balady,Michael H. Criqui,Gerald F. Fletcher,Philip Greenland,Loren F. Hiratzka,Nancy Houston-Miller,Penny M. Kris-Etherton,Harlan M. Krumholz,John C. LaRosa,Ira S. Ockene,Thomas A. Pearson,James Reed,Reginald L. Washington,Sidney C. Smith +14 more
TL;DR: The Framingham Heart Study has contributed importantly to understanding of the causes of coronary heart disease (CHD), stroke, and other cardiovascular diseases as mentioned in this paper, and the NCEP guidelines adjust the intensity of cholesterol-lowering therapy with absolute risk as determined by summation of risk factors.
Journal ArticleDOI
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
TL;DR: Niacin-induced changes in serum lipid levels produce significant improvements in both coronary artery disease and clinical outcomes, and is ideal for treating a wide variety of lipid disorders, including the metabolic syndrome, diabetes mellitus, isolated low high-density lipoprotein cholesterol, and hypertriglyceridemia.
Journal ArticleDOI
Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.
TL;DR: In this article, the effects of treating rheumatoid arthritis with antirheumatic drugs on abnormal lipid levels were evaluated in 42 patients who had not been treated with corticosteroids or disease-modifying antiretracting drugs.
Journal ArticleDOI
Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease A Working Group Report
TL;DR: The case has been made for considering HDL-C in tandem with triglycerides (TG) as synergistic coronary risk factors, and areas requiring further research are identified.
Journal Article
Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey.
Hyon K. Choi,John D. Seeger +1 more
TL;DR: These national survey data indicate that RA not treated with DMARD or glucocorticoids is associated with adverse lipid profiles characterized by lower HDL-C and apolipoprotein A-I levels in persons aged > or = 60 years.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Book
Statistical Principles in Experimental Design
TL;DR: In this article, the authors introduce the principles of estimation and inference: means and variance, means and variations, and means and variance of estimators and inferors, and the analysis of factorial experiments having repeated measures on the same element.
Journal ArticleDOI
Statistical Principles in Experimental Design
TL;DR: This chapter discusses design and analysis of single-Factor Experiments: Completely Randomized Design and Factorial Experiments in which Some of the Interactions are Confounded.
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
High density lipoprotein as a protective factor against coronary heart disease: The Framingham study
TL;DR: The major potent lipid risk factor was HDL cholesterol, which had an inverse association with the incidence of coronary heart disease in either men or women and these associations were equally significant even when other lipids and other standard risk factors for coronaryHeart disease were taken into consideration.